Nu Skin, Toyo venture
This article was originally published in The Tan Sheet
Executive Summary
Provo, Utah-based direct seller Nu Skin Enterprises announces a memorandum of understanding with Toyo Bio-Pharma for a joint research and development relationship. Toyo Bio-Pharma, a natural products manufacturer in the U.S. and Japan, and Nu Skin established the NU Toyo Research joint venture in the U.S. to facilitate the agreement, the firms say July 28. The agreement aims at "sharing scientific and regulatory insights" and developing cosmeceutical and nutraceutical products for sale through Nu Skin's worldwide network, the firms say...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.